Myovant Sciences Ltd. (NYSE:MYOV)

Biotech’s products, harnessing the latest science and designed and engineered to heal and improve the quality and length of human life, enjoy inexhaustible demand.

And as that science advances so do the cures, and the profit opportunities for biotech investors. We’re on the threshold of finding cures for the most debilitating diseases like cancer, Alzheimer’s and heart disease

These new cures bring the potential for dizzying gains.

You see, there are numerous discrete events that can have earth-shattering impacts on a company's share price.

There are buyouts and mergers just as with any other type of business, but there are also lucrative partnerships that are signed to develop a promising new therapeutic. Plus, the biotech calendar is rich in events like clinical trials initiated or completed, data releases from these trials and the FDA's regulatory decisions.

These regulatory decisions come with dates... and the FDA is very good at meeting its decision schedule. Few sectors can give you such defined events. They often make perfect trading plays.

And the market has never been more bullish on biotech, taking shares to record highs this month.

The wealth potential isn’t lost on people in the finance sector. One example is Vivek Ramaswamy, who emerged at a young age from the world of finance when he left an investment management company to found his own biotech empire.

The wunderkind founded Roivant Sciences, which went public in 2015. Roivant went on to start or spin off more than a dozen subsidiaries. And Ramaswamy’s biotech empire spans companies specializing in everything from companies looking to cure neurodegenerative diseases to gene therapy and cardiovascular diseases.

One of the companies he founded, Myovant Sciences (NYSE: MYOV), is dedicated to women’s health and prostate cancer.

The company’s pipeline of drugs in development include treatments for female infertility, uterine fibroids, endometriosis and prostate cancer.

Because there’s a huge opportunity in Myovant right around the corner!

The company has taken its prostate cancer drug, relugolix, through several expensive clinical trials.

The drug is so promising, the FDA has granted it priority review. The regulatory agency has set a decision date for Dec. 20, 2020. On that date, the FDA will issue its decision on whether or not Myovant can market relugolix for the treatment of prostate cancer.

Myovant’s clinical trials for relugolix reveals that the odds of approval are very good.

this stock has seen huge insider interest in buying $11MM. Also moving over the 55 Moving Avg for quite some time. I believe it will keep moving for some time.